Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients

Journal of Clinical Oncology

Volumn 23, Issue 22, 2005, Pages 5007-5018

  Cappuzzo, Federico ^a   Varella Garcia, Marileila ^a   Shigematsu, Hisayuki ^a   Domenichini, Irene ^a   Bartolini, Stefania ^a   Ceresoli, Giovanni L ^a   Rossi, Elisa ^a   Ludovini, Vienna ^a   Gregorc, Vanesa ^a   Toschi, Luca ^a   Franklin, Wilbur A ^a   Crino, Lucio ^a   Gazdar, Adi F ^a   Bunn Jr , Paul A ^a   Hirsch, Fred R ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; QUINAZOLINE DERIVATIVE;

ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA SEQUENCE; EXON; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE MUTATION; GENE NUMBER; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT RESPONSE; BLOOD; COHORT ANALYSIS; GENE DOSAGE; GENE EXPRESSION PROFILING; GENETICS; LUNG TUMOR; NUCLEOTIDE SEQUENCE; PROTO ONCOGENE; SURVIVAL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; GENE DOSAGE; GENE EXPRESSION PROFILING; GENES, ERBB-2; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 24644445676     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.09.111     Document Type: Article

References (48)

1. Greenlee RT, Hill-Harmon MB, Murray T, et al: Cancer statistics, 2001. CA Cancer J Clin 51:15-36, 2001
2. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 311:899-909, 1995
3. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002
4. Kelly K, Crowley J, Bunn PA Jr, et al: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial. J Clin Oncol 19:3210-3218, 2001
5. Mendlsohn J, Baserga J: The EGF receptor family as targets for cancer therapy. Oncogene 19:6550-6565, 2000
6. De Bono JS, Rowinsky EK: The ErbB receptor family: A therapeutic target for cancer. Trends Mol Med 8:19-26, 2002
7. Woodburn JR: The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82:241-250, 1999
8. Arteaga CL: Epidermal growth factor receptor dependence in human tumors: More than just expression? Oncologist 7:31-39, 2002
9. Brabender J, Danenberg KD, Metzger R, et al: Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 7:1850-1855, 2001
10. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
11. Onn A, Correa AM, Gilcrease M, et al: Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res 10:136-143, 2004
12. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al: Epidermal growth factor receptor in non-small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21:3798-3807, 2003
13. Hirsch FR, Varella-Garcia M, Franklin WA, et al: Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br J Cancer 86:1449-1456, 2002
14. Ciardiello F, De Vita F, Orditura M, et al: Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials. Expert Opin Emerg Drugs 8:501-514, 2003
15. Ciardiello F, Caputo R, Bianco R, et al: Antitumour effect and potentiation of cytotoxic drug activity in human cancer cells by ZD1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 6:2053-2063, 2000
16. Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21:2237-2246, 2003
17. Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 290:2149-2158, 2003
18. Miller VA, Patel J, Shah N, et al: The epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) shows promising activity in patients with bronchioloalveolar cell carcinoma (BAC): Preliminary results of a phase II trial. Proc Am Soc Clin Oncol 22:619, 2003 (abstr 2491)
19. Shepherd FA, Pereira J, Ciuleanu TE, et al: A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy: A National Cancer Institute of Canada Trial Group (NCIC CTG) trial. J Clin Oncol 23:622, 2004 (suppl; abstr 7022)
20. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004
21. Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004
22. Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancer from "never-smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:13306-13311, 2004
23. Cappuzzo F, Hirsch FR, Rossi E, et al: Epidermal growth factor receptor gene copy number, gene mutations and protein level predict outcome to gefitinib therapy in advanced non-small cell lung cancer. J Natl Cancer Inst 97:643-655, 2005
24. Hirsch FR, Varella-Garcia M, McCoy J, et al: Increased EGFR gene copy numbers detected by FISH associates with increased sensitivity to gefitinib in patients with bronchioalveolar carcinoma cell types-A Southwest Oncology Group study. J Clin Oncol (in press)
25. Cappuzzo F, Magrini E, Ceresoli GL, et al: AKT phosphorylation and gefitinib efficacy in patients with advanced Non-Small Cell Lung Cancer. J Natl Cancer Inst 6:1133-1141, 2004
26. Sordella R, Bell DW, Haber DA, et al: Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305:1163-1167, 2004
27. Ono M, Hirata A, Kometani T, et al: Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol Cancer Ther 3:465-472, 2004
28. Tzahar E, Waterman H, Chen X, et al: A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 16:5276-5287, 1996
29. Moasser MM, Basso A, Averbuch S, et al: The tyrosine kinase inhibitor ZD1839 ('Iressa') inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 61:7184-7188, 2001
30. Moulder SL, Yakes FM, Muthuswamy SK, et al: Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 61:8887-8895, 2001
31. Anido J, Matar P, Albanell J, et al: ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/ HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin Cancer Res 9:1274-1283, 2003
32. Gandara DR, West H, Chansky K, et al: Bronchioloalveolar carcinoma: A model for investigating the biology of epidermal growth factor receptor inhibition. Clin Cancer Res 10:4205s-4209s, 2004
33. Cappuzzo F, Gregorc V, Rossi E, et al: Gefitinib in pretreated non-small-cell lung cancer (NSCLC): Analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol 21:2658-2663, 2003
34. Stephens P, Hunter C, Bignell G, et al: Lung cancer: Intragenic ERBB2 kinase mutations in tumours. Nature 431:525-526, 2004
35. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
36. Travis WD, Colby TV, Corrin B, et al: Histological Typing of Lung and Pleural Tumors (ed 3). Berlin, Germany, Springer, 1999
37. Shigematsu H, Takahashi T, Nomura M, et al: Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 65: 1642-1646, 2005
38. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1985
39. Hosmer DW, Lemeshow S: Applied Logistic Regression. New York, NY, Wiley & Sons, 1989
40. Normanno N, Campiglio M, De LA, et al: Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 13:65-72, 2002
41. Pelosi G, Del Curto B, Dell'Orto P, et al: Lack of prognostic implications of HER2/neu abnormalities in 345 stage I nonsmall cell carcinomas (NSLCL) and 207 stage I-III neuroendocrine tumors (NET) of the lung. Int J Cancer 113:101-108, 2005
42. Tan D, Deeb G, Wang J, et al: HER/2neu protein expression and gene alteration in stage I-IIIA non-small cell lung cancer: A study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry and fluorescent in situ hybridization. Diagn Mol Pathol 12:201-211, 2003
43. Hirsch FR, Varella-Garcia M, Franklin WA, et al: Evaluation of HER2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br J Cancer 86:1449-1456, 2002
44. Al-Kuraya K, Schraml P, Torhorst J, et al: Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res 64:8534-8540, 2004
45. Miller VA, Kris MG, Shah N, et al: Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 22:1103-1109, 2004
46. Shigematsu H, Lin L, Takahashi T, et al: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97:339-346, 2005
47. Gatzemeier U, Groth G, Butts C, et al: Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol 1:19-27, 2004
48. Langer CJ, Stephenson P, Thor A, et al: Trastuzumab in the treatment of advanced non-small-cell lung cancer: Is there a role? Focus on Eastern Cooperative Oncology Group study 2598. J Clin Oncol 22:1180-1187, 2004